Publication | Closed Access
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
22
Citations
0
References
2020
Year
Anti-tigit AntibodyAnti-pd-1/pd-l1-naive NsclcImmunologyTherapeutic EfficacyImmune Checkpoint InhibitorPharmacotherapyImmunotherapyMedicineNovel Therapy
No additional data available for this publication yet. Check back later!